NCT06658405 2026-03-18
HPV2
Centre Oscar Lambret
Phase 2 Recruiting
Clinical Trials
113 trialsNCT04486378 2026-03-17
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
BioNTech SE
Phase 2 Recruiting
NCT07002034 2026-03-16
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
Reunion Neuroscience Inc
Phase 2 Recruiting
NCT07252739 2026-03-16
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT07387471 2026-03-16
Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
AbbVie
Phase 2 Recruiting
NCT01042379 2026-03-13
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT07023289 2026-03-13
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
AbbVie
Phase 2 Recruiting
NCT07469683 2026-03-13
An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Yonsei University
Phase 2 Recruiting
NCT07050771 2026-03-12
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
The Methodist Hospital Research Institute
Phase 2 Recruiting
NCT04449549 2026-03-09
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT06915116 2026-03-06
Acupuncture for People Experiencing Period Loss Due to Chemotherapy
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06979596 2026-03-06
OMAHA-015
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT07169851 2026-03-06
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
Eli Lilly and Company
Phase 2 Recruiting
NCT06807593 2026-03-05
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07205731 2026-03-05
SAFE ESO
University Hospital, Clermont-Ferrand
Phase 2 Recruiting
NCT05065801 2026-03-04
GABRINOX2
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 2 Recruiting
NCT07024784 2026-03-04
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
AbbVie
Phase 2 Recruiting
NCT05283720 2026-03-03
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
Phase 2 Recruiting
NCT05681195 2026-03-03
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
Baptist Health South Florida
Phase 2 Recruiting
NCT06801041 2026-03-03
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06806930 2026-03-03
Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)
George Washington University
Phase 2 Recruiting
NCT07072728 2026-03-03
Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
Psyence Australia Pty Ltd
Phase 2 Recruiting
NCT06435286 2026-03-02
Effectiveness and Performance of an Optical Biopsy Technology for Esophageal Cancer in Brazil and the United States
Baylor College of Medicine
Phase 2 Recruiting
NCT07282834 2026-02-27
Charlie-2
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Phase 2 Recruiting
NCT07193394 2026-02-23
H3RAKLES
Institut Curie
Phase 2 Recruiting
NCT04337580 2026-02-20
FASN
Wake Forest University Health Sciences
Phase 2 Recruiting
NCT05879146 2026-02-19
Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT02693535 2026-02-13
TAPUR
American Society of Clinical Oncology
Phase 2 Recruiting
NCT07404176 2026-02-11
TENET
Tata Memorial Hospital
Phase 2 Recruiting
NCT04895436 2026-02-09
ReVenG
AbbVie
Phase 2 Recruiting
NCT06129747 2026-02-09
Repeat Breast Conserving Surgery Followed by Daily Partial Breast Irradiation in Ipsilateral Breast
Case Comprehensive Cancer Center
Phase 2 Recruiting
NCT06593522 2026-02-05
A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
Amgen
Phase 2 Recruiting
NCT07227610 2026-02-05
Brain Metastases in Greater Size - Hypofractionated Options Trial (BIGSHOT)
Medical University of South Carolina
Phase 2 Recruiting
NCT06417190 2026-02-04
Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology
Cedars-Sinai Medical Center
Phase 2 Recruiting
NCT06788938 2026-02-02
Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT07381231 2026-02-02
I-APT
Samsung Medical Center
Phase 2 Recruiting
NCT05796375 2026-01-30
ReplaceCysto
White River Junction Veterans Affairs Medical Center
Phase 2 Recruiting
NCT06323473 2026-01-23
Maitake
The Canadian College of Naturopathic Medicine
Phase 2 Recruiting
NCT06201884 2026-01-12
APPAHOCA-2
Centre Francois Baclesse
Phase 2 Recruiting
NCT06848348 2026-01-12
Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain
Dogwood Therapeutics Inc.
Phase 2 Recruiting
NCT05152472 2026-01-08
ATEZOGIST
Centre Leon Berard
Phase 2 Recruiting
NCT06680089 2025-12-31
CD70-targeted immunoPET Imaging of Kidney Cancer
RenJi Hospital
Phase 2 Recruiting
NCT06108232 2025-12-19
Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05257590 2025-12-17
CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma
TaiRx, Inc.
Phase 2 Recruiting
NCT07284589 2025-12-16
Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake
Nuclear Imaging Institute
Phase 2 Recruiting
NCT04570943 2025-12-05
GABRINOX-ART
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 2 Recruiting
NCT06333314 2025-12-02
Pan-MSI-ACSE
UNICANCER
Phase 2 Recruiting
NCT05099471 2025-11-28
VIWA-1
University of Ulm
Phase 2 Recruiting
NCT06846346 2025-11-28
GRACIE
UNICANCER
Phase 2 Recruiting
NCT06458036 2025-11-25
RAISE
Children's Hospital of Philadelphia
Phase 2 Recruiting